Redeye interviews Mentice’s CEO Frans Venker and CFO Ulrika Drotz Voksepp.
Redeye comments on SHH´s fourth quarter. SSH posted a growth of 23% Y/Y, and EBITDA margin of 25%.
Minor estimate changes Potential start of variable revenue acceleration EV/ARR 2x, '25e EV/EBITDA ~8...
Redeye states that BeammWave’s report was unsurprising.
Redeye provides an update on Acarix following its year-end report, which showed softer-than-expected...
Redeye updates on Invisio following its strong Q4-results and a continued positive outlook for 2025E...
Redeye comments on Alligator Bioscience's Q4 report and the rights issue, which was subscribed to 54...
Relais' Q4 report was above LSEG consensus expectations, supported by strong 9% y/y organic revenue ...
Redeye provides an update following SenzaGen’s Q4 2024 report.
Redeye comments on Lytix Biopharma's Q4 report. During the quarter, Verrica reported further progres...
Redeye provides its comment on Mendus’ Q4 2024 report.
Redeye updates its estimates and valuation following Mentice’s Q4 2024 report.
Strong EBIT of SEK 437m (ABGSCe 495m) in Q4 New targets: 15% ROE and total '25-'27 EBIT SEK 1.
Q4: Sales in line, but EBIT beat on strong GM We slightly cut our sales estimate, but raise adj.
Redeye returns following IRLAB's Q4 report and recent news in the company.
Sales decline continued, but solid cost control, comps ease from here Cut sales by 2%, EBIT by SEK 3...
Redeye comments in Invisio’s Q4-results which were in line with the preannounced results.
Q4 already pre-announced, orders +18% vs cons TAM updated from SEK 14bn to 25bn (+80%) Positive 2025...
Endomines successfully capitalized on the increased gold market prices during the second half of the...
Solteq’s Q4 performance mirrored its full-year trends, with declining sales but improved profitabili...
